BELLUS Health (TSX:BLU)
Historical Stock Chart
1 Year : From Oct 2018 to Oct 2019
LAVAL, QC, April 4, 2019 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, at two upcoming healthcare investor conferences.
Conference Presentation Details:
Event: Needham & Company 18th Annual Healthcare Conference
Date/Time: Wednesday, April 10, 2019 at 3:30 p.m. ET
Location: New York, NY
Event: Bloom Burton & Co. Healthcare Investor Conference
Date/Time: Wednesday, May 1, 2019 at 9:30 a.m. ET
Location: Toronto, ON
Live webcasts from the Needham and Bloom Burton conference presentations may be accessed on the Events and Presentations page under the Investors & News section of the Company's website. Following the events, archived webcasts and presentations will be available on the BELLUS Health website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's lead drug candidate, BLU-5937, is being developed for the treatment of chronic cough.
Chronic cough is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in the United States suffer from chronic cough with more than 2.6 million having unexplained or refractory chronic cough lasting for more than a year. There are limited treatment options for refractory chronic cough including no currently approved therapeutics.
SOURCE BELLUS Health Inc.